The pharmaceutical company Double Bond Pharma reports decreased revenue during the fourth quarter compared with the same period a year earlier. The operating result showed a loss versus the prior period’s profit.Revenue fell to just under 23,000 kronor (217,303).The operating result was -0.5 million kronor (4.2). Earnings both before and after tax were 1.7 million kronor (1.2). No ordinary dividend is proposed. Cash and cash equivalents amounted to 1.1 million kronor (3.9)."2025 has been a breakthrough year for Double Bond Pharmaceutical. The progress we have made confirms that our commitment to SI053/Temodex has been exactly the right priority, and we now look to the future with very strong confidence. Our primary focus remains to accelerate the development of SI053 for the treatment of glioblastoma (GBM), with the goal of identifying the right partner for the product’s continued clinical path and commercialization," comments CEO Igor Lokot.Double Bond Pharma, million kronorQ4-2025Q4-2024ChangeNet sales0.030.22-86.4%Operating result-0.54.2Operating margin1,909.1%Profit before tax1.71.241.7%Net profit1.71.241.7%Cash and cash equivalents1.13.9-71.8%Ordinary annual dividend per share, kronor0